AbbVie Shares Tumble After $63 Billion Allergan Deal

The video discusses the merger between Allergan and AbbVie, highlighting the financial and strategic aspects of the deal. It explores the market's reaction, including skepticism and stock fluctuations. The discussion also covers the valuation gap and potential regulatory challenges, drawing parallels with the Bristol Myers and Celgene merger. The merger aims to buy time for both companies to address future competition and sales challenges, despite lacking new pipeline drugs.

What challenges did the Bristol Myers and Celgene deal face that might be relevant to the AbbVie-Allergan merger?

What is the significance of the US Federal Trade Commission's involvement in the merger process?